Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Assets (2018 - 2025)

Dna X's Assets history spans 8 years, with the latest figure at $43.9 million for Q4 2025.

  • Quarterly results put Assets at $43.9 million for Q4 2025, up 10.47% from a year ago — trailing twelve months through Dec 2025 was $43.9 million (up 10.47% YoY), and the annual figure for FY2025 was $43.9 million, up 10.47%.
  • Assets for Q4 2025 was $43.9 million at Dna X, up from $40.2 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $58.6 million in Q3 2023 to a low of $36.0 million in Q1 2025.
  • The 5-year median for Assets is $41.7 million (2021), against an average of $44.5 million.
  • The sharpest move saw Assets crashed 42.8% in 2021, then soared 44.11% in 2023.
  • Year by year, Assets stood at $41.1 million in 2021, then surged by 30.65% to $53.7 million in 2022, then grew by 4.39% to $56.0 million in 2023, then dropped by 29.09% to $39.7 million in 2024, then grew by 10.47% to $43.9 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $43.9 million, $40.2 million, and $36.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.